Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,875.00    180.00 (2.69%)
Bid:
6,870.00
Ask:
6,880.00
Spread: 10.00 (0.146%)
Market Cap: £5.07b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

7 Nov 2012 07:00

RNS Number : 4867Q
Spirax-Sarco Engineering PLC
07 November 2012
 



News Release

 

Wednesday 7th November 2012

INTERIM MANAGEMENT STATEMENT

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st July 2012 to 6th November 2012.

 

Trading

In the four months ended 31st October, organic sales increased 6%, ahead of the rate of growth reported in the first half year. Notably, Asia Pacific and Watson-Marlow achieved strong double-digit sales growth in the period, followed by a more modest advance in the Americas and slightly reduced sales in our Europe, Middle East and Africa (EMEA) segment. Sales in sterling were ahead 2% in the first ten months of 2012, after including the impact of unfavourable currency movements and two small disposals last year.

 

As anticipated, our trading performance in the four months ended 31st October improved with operating profit 8% ahead at constant currency. Better results were particularly evident in Watson-Marlow, where the planned increases in R&D and market development costs in the first half year are unwinding in the second half. Results also improved in EMEA, as the cost base in Europe is being progressively lowered and the profitability of our Supply operations increased. For the ten months ended 31st October 2012, operating profit was therefore 2% ahead of last year at constant currency, compared with a decline of 3% for the first half year.

 

Financial position

We continue to operate with a strong balance sheet and are steadily reducing and rebalancing our stock position in Europe, although this continues to have a negative impact on the factory loading in our main manufacturing plants in the UK and France. Net cash balances at the end of October 2012 increased to £43m compared with £9m at 30th June 2012, although the interim dividend of £12m will be paid on 9th November. There were no significant events or transactions during the period that resulted in a material impact on the financial position of the Group. The principal risks and uncertainties remain those set out on pages 26 and 27 of the 2011 Annual Report.

 

Outlook

Global macro-economic conditions have weakened in recent months as reflected in slowing rates of GDP growth and industrial output in most geographic regions. Trading conditions in many of our markets have, however, remained more resilient and we have not seen softening in underlying demand. The Group has a favourable weighting to defensive industries such as food & beverage, pharmaceuticals and health care, and maintenance spending by our customers has continued to be positive, even against the deterioration in economic conditions.

 

Our business has other resilient characteristics due to our diverse geographic, industry, customer and product spread, and the large proportion of our sales that derive from maintenance or operating spend by our customers. We are seeing the improvements in our Supply organisation from the site consolidation in the UK and from the previously announced cost reduction programme in Europe, which should be complete by the year-end.

 

Although our forward visibility remains short and we are not immune to a worsening in our markets, which can be reflected fairly quickly in our mid-cycle business, the Board continues to expect the Group to make progress for the full year.

 

 

Enquiries:

Mark E Vernon, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note

All references above are to adjusted trading results that exclude non-operational items, including the previous announced restructuring costs, amortisation of acquisition-related intangible assets and acquisition and disposal costs.

 

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBUGGBGDL
Date   Source Headline
21st Nov 20173:08 pmRNSDirector/PDMR Shareholding
21st Nov 20177:00 amRNSTrading Statement
14th Nov 201710:39 amRNSDirector/PDMR Shareholding
16th Oct 20175:35 pmRNSDirector/PDMR Shareholding
29th Sep 20173:36 pmRNSHolding(s) in Company
9th Aug 20177:00 amRNSHalf-year Report
4th Jul 20177:00 amRNSCompletion of Acquisition
23rd Jun 20179:11 amRNSTotal Voting Rights
20th Jun 20173:59 pmRNSHolding(s) in Company
12th Jun 20172:20 pmRNSDirector/PDMR Shareholding
5th Jun 20179:08 amRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSAcquisition of Chromalox for US$415 million
9th May 20174:30 pmRNSResult of AGM
9th May 20177:00 amRNSTrading Statement
4th May 20174:30 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSCompletion of Acquisition
26th Apr 20178:42 amRNSHolding(s) in Company
25th Apr 20179:10 amRNSHolding(s) in Company
19th Apr 20173:55 pmRNSHolding(s) in Company
18th Apr 20173:58 pmRNSHolding(s) in Company
3rd Apr 20177:30 amRNSAcquisition
24th Mar 20174:44 pmRNSTotal Voting Rights
23rd Mar 20171:45 pmRNSDirector/PDMR Shareholding
17th Mar 20174:04 pmRNSDirector/PDMR Shareholding
9th Mar 20177:00 amRNSFinal Results
30th Nov 20167:00 amRNSAcquisition
22nd Nov 20167:00 amRNSTrading Statement
17th Nov 20164:23 pmRNSDirector/PDMR Shareholding
14th Nov 20168:30 amRNSDr Krishnamurthy Rajagopal
10th Nov 201611:40 amRNSListing Application
8th Nov 201611:57 amRNSChange of Director Details
4th Nov 20164:27 pmRNSTotal Voting Rights
28th Oct 20167:00 amRNSBoard Succession Changes
17th Oct 20162:49 pmRNSAdditional Listing
14th Oct 20165:03 pmRNSDirector/PDMR Shareholding
14th Oct 20163:20 pmRNSTotal Voting Rights
14th Oct 20163:17 pmRNSBlock listing Interim Review
6th Oct 201611:48 amRNSNotification of Release Date - Trading Statement
8th Sep 201612:44 pmRNSTotal Voting Rights
18th Aug 20168:30 amRNSBoard Appointment
12th Aug 20163:51 pmRNSDirector/PDMR Shareholding
9th Aug 20167:05 amRNSSpirax Sarco acquires assets of Hiter for £3.9 m
9th Aug 20167:00 amRNS2016 Half Year Results
5th Aug 20162:56 pmRNSTotal Voting Rights
1st Jul 201611:43 amRNSTotal Voting Rights
29th Jun 20169:29 amRNSNotice of Results
21st Jun 20165:40 pmRNSDirector/PDMR Shareholding
10th Jun 20162:59 pmRNSHolding(s) in Company
2nd Jun 20164:20 pmRNSAdditional Listing
2nd Jun 20163:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.